|
|
|
|
| LEADER |
00000cam a2200000Ma 4500 |
| 001 |
EBSCO_ocn990408952 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr |n|---||||| |
| 008 |
170624s2017 ts o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d MERUC
|d YDX
|d OCLCQ
|d N$T
|d AGLDB
|d IGB
|d OCLCF
|d AUW
|d BTN
|d MHW
|d INTCL
|d SNK
|d OCLCQ
|d G3B
|d S8I
|d S8J
|d STF
|d D6H
|d OCLCQ
|d UKAHL
|d OCLCO
|d K6U
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 990754270
|
| 020 |
|
|
|a 9781681081878
|q (electronic bk.)
|
| 020 |
|
|
|a 1681081873
|q (electronic bk.)
|
| 029 |
1 |
|
|a AU@
|b 000069026698
|
| 029 |
1 |
|
|a AU@
|b 000070590546
|
| 035 |
|
|
|a (OCoLC)990408952
|z (OCoLC)990754270
|
| 050 |
|
4 |
|a RM332.3
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.398
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Anti-obesity drug discovery and development.
|n Volume 3 /
|c editors, Atta-ur-Rahman, M. Iqbal Choudhary.
|
| 260 |
|
|
|a Sharjah :
|b Bentham Science Publishers,
|c 2017.
|
| 300 |
|
|
|a 1 online resource (245 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a PREFACE; List of Contributors ; Current Status of Medical Therapy and New Targets for Anti-Obesity Drug Development ; Chihiro Okuma, Yukihito Ishii and Takeshi Ohta*; INTRODUCTION; Approved Drugs; Phentermine; Mazindol; Fenfluramine/Dexfenfluramine; Orlistat; Shibutramine; Rimonabant; Qsymia; BELVIQ (Lorcaserin); Contrave; New Drug Targets (Table 3); Late Phase Clinical Development; Early Phase Clinical Stage Development or Pre-Clinical Development Stage Late Phase Clinical Development; Future Prospects; Obesity Animal Models; ob/ob Mouse; db/db Mouse; KK-Ay Mouse; TSOD Mouse.
|
| 505 |
8 |
|
|a SDT fatty RatZF Rat; ZDF Rat; cp/cp Rat; WBN/Kob fatty Rat; DIO Models; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Unravelling Potential Anorexigen Effects of Nesfatin-1: How Homeostatic Mechanisms Help Balance Excess Calories ; Carmine Finelli*; INTRODUCTION; Nesfatin-1/NUCB-2 and Anorexigenic Effect; The Oxytocin Pathway in Nesfatin-1's Inhibitory Effect on Food Intake; Nesfatin-1 and CRF; Nesfatin-1 and Anti-Obesity Treatment; Nesfatin-1 and Food Behaviour Control; Nesfatin-1 and Signaling Pathway; Nesfatin-1 and Eating Disorders; CONCLUSIVE REMARKS; CONFLICT OF INTEREST.
|
| 505 |
8 |
|
|a ACKNOWLEDGEMENTSABBREVIATIONS; REFERENCES; Proteomics in the Characterization of New Target Therapies in Pediatric Obesity Treatment ; Gillian E. Walker1,*, Marilisa De Feudis1, Marta Roccio1, Gianni Bona2 and Flavia Prodam2; INTRODUCTION; CHILDHOOD OBESITY: PATHOLOGICAL BASIS; Genetic Considerations for Childhood Obesity; Energy Homeostasis Dysregulation; Pathophysiology of Adipose Tissue; PROTEOMICS; Gel Based Methods; Non Gel Based Methods: Mass Spectrometry (MS); Chips; Challenges; PROTEOMIC STUDIES OF ADIPOSE TISSUE; WAT Depots; WAT Secretome; BAT; Stromal-Vascular Fraction (SVF).
|
| 505 |
8 |
|
|a PROTEOMIC STUDIES IN ADIPOCYTES: STEM CELLS AND CELL LINESAdipogenesis: Adipo-proteomics; Murine 3T3-L1 Preadipocytes; Adipocyte-Derived Stem Cells (ASCs); Adipocyte Secretome; Post-Translational Modifications (PTMs); PROTEOMIC PROFILING: TISSUES AND CIRCULATION; Fetal Programming: Tissue-Specific Biomarkers; Circulating Biomarkers; Urine Biomarkers; OUTLOOKS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; ABBREVIATIONS; REFERENCES.
|
| 505 |
8 |
|
|a Relationship Between Hormonal Milieu and Oxidative Stress in Childhood Obesity: A Physiopathological Basis for Antioxidant Treatment and Prevention of Cardiovascular Risk Antonio Mancini*, Francesco Leo, Chantal Di Segni, Sebastiano Raimondo and Aurora Natalia Rossodivita; INTRODUCTION; OBESITY AND OXIDATIVE STRESS; Hormones and Inflammatory Molecules Produced by or Related to Adipose Tissue; Oxidative Stress in Childhood Obesity; HORMONAL REGULATION OF ANTIOXIDANT SYSTEMS AND THEIR DERANGEMENT IN CHILDHOOD OBESITY; Growth Hormone (GH); Thyroid; Adrenal Glands; Gonads.
|
| 500 |
|
|
|a Adipose tissue (Leptin and Kisspeptin).
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Appetite depressants.
|
| 650 |
|
0 |
|a Obesity.
|
| 650 |
|
2 |
|a Appetite Depressants
|
| 650 |
|
2 |
|a Obesity
|
| 650 |
|
6 |
|a Anorexigènes.
|
| 650 |
|
6 |
|a Obésité.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Appetite depressants
|2 fast
|
| 650 |
|
7 |
|a Obesity
|2 fast
|
| 700 |
1 |
|
|a Rahman, Atta-ur-
|
| 700 |
1 |
|
|a Choudhary, M. Iqbal.
|
| 776 |
0 |
8 |
|i Print version:
|a Rahman, Atta-ur.
|t Anti-Obesity Drug Discovery and Development Volume 3.
|d Sharjah : Bentham Science Publishers, ©2017
|z 9781681081885
|
| 830 |
|
0 |
|a Anti-Obesity Drug Discovery and Development.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1536043
|z Texto completo
|
| 938 |
|
|
|a Askews and Holts Library Services
|b ASKH
|n AH37580972
|
| 938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL4877812
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1536043
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 14592203
|
| 994 |
|
|
|a 92
|b IZTAP
|
